Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(naltrexone oral )
817 results
  • Medication Treatment of Opioid Use Disorder. [Review]
    Biol Psychiatry 2019Bell J, Strang J
  • Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist). Methadone and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of ot…
  • Use of naltrexone in treating opioid use disorder in pregnancy. [Journal Article]
    Am J Obstet Gynecol 2019Towers CV, Katz E, … Visconti K
  • CONCLUSIONS: These study data demonstrate that in pregnant women who choose to completely detoxify off opioid drugs during gestation, naltrexone, as a continued form of medication assisted treatment, is a viable option for some pregnant patients who suffer from opioid use disorder. Naltrexone crosses the placenta and maternal and fetal levels are concordant. Because naltrexone clears quickly from the maternal circulation, this rapid clearance needs to be addressed with patients. This is important because maternal relapse could occur in a short time-period if the oral drug is discontinued without the knowledge of their healthcare providers. Nonetheless, the drug is well-tolerated by both mother and fetus and newborns do not experience symptoms of NAS if naltrexone MAT is maintained to delivery.
  • Court personnel attitudes towards medication-assisted treatment: A state-wide survey. [Journal Article]
    J Subst Abuse Treat 2019; 104:72-82Andraka-Christou B, Gabriel M, … Silverman RD
  • CONCLUSIONS: As expected, court employees' attitudes significantly differ by medication, with average attitudes towards agonist medications being more negative than attitudes towards extended-release naltrexone. Despite a larger evidence base for the efficacy of methadone and oral buprenorphine, justice personnel may have more positive attitudes towards extended-release naltrexone due to targeted marketing by the pharmaceutical manufacturer, fears about diversion or misuse of agonist medications, and historic criminal justice hostility towards agonist medications. Importantly, previous education/training regarding MAT is associated with more positive attitudes, suggesting that more awareness-raising or capacity building educational interventions are needed, especially for prosecutors and law enforcement personnel.
  • Circumstances of death of opioid users being treated with naltrexone. [Journal Article]
    Addiction 2019Darke S, Farrell M, … Lappin J
  • CONCLUSIONS: The primary cause of death among people undergoing naltrexone treatment for opioid dependence in Australia from 2000 to 2017 was opioid toxicity, the majority of cases having been maintained on oral naltrexone. Cases in which naltrexone was not detected indicate the importance of treatment compliance. Deaths due to opioid toxicity where naltrexone was present indicates the possibility of overdose while naltrexone medication is maintained.
  • Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy. [Case Reports]
    Cureus 2019; 11(3):e4225Zashin S
  • Sjogren's Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. In addition, fatigue and musculoskeletal pain, often described as aching, is very common. Treatment directed toward alleviating the fatigue and pain associated with Sjogren's is currently very limited. This report describes a case of a 4…
New Search Next